Search Results

Viewing Page 6 of 23 | Showing Results 51 - 60 of 222

A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK)...

Krish Patel, MD

Swedish Cancer Institute

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies

A Phase 1 Dose-Escalation Study of VLS-101 in Hematological Malignancies

Krish Patel, M.D.

Swedish Cancer Institute

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

The primary objectives of the study are: Phase 1: To assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a...

William Bensinger, M.D.

Swedish Cancer Institute

Reducing Health Disparities at End-of-Life

This project will test interactive, web-based training materials designed for health care providers to learn or improve cross-cultural...

Ardith Doorenbos, PhD, RN

Breast Cancer WEight Loss Study (BWEL Study)

 

Gary Goodman, MD
Swedish Cancer Institute

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer (AMBASSADOR)

 

Gary Goodman, MD
Swedish Cancer Institute
Viewing Page 6 of 23 | Showing Results 51 - 60 of 222